Kezar Life Sciences (KZR)
(Real Time Quote from BATS)
$0.58 USD
+0.01 (0.87%)
Updated Sep 18, 2024 02:30 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Kezar Life Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 201 | 277 | 208 | 140 | 78 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 9 | 3 | 4 | 3 |
Total Current Assets | 207 | 286 | 212 | 145 | 81 |
Net Property & Equipment | 4 | 3 | 3 | 3 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 1 | 0 | 0 | 0 |
Total Assets | 221 | 300 | 218 | 152 | 90 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 2 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 6 | 5 | 3 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 18 | 11 | 8 | 6 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 10 | 10 | 10 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34 | 30 | 21 | 11 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 538 | 520 | 378 | 267 | 163 |
Retained Earnings | -351 | -249 | -181 | -126 | -84 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 188 | 270 | 197 | 141 | 78 |
Total Liabilities & Shareholder's Equity | 221 | 300 | 218 | 152 | 90 |
Total Common Equity | 188 | 270 | 197 | 141 | 78 |
Shares Outstanding | 72.60 | 68.30 | 49.10 | 46.20 | 19.10 |
Book Value Per Share | 2.58 | 3.95 | 4.01 | 3.05 | 4.09 |
Fiscal Year End for Kezar Life Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 164 | 180 | 201 | 218 | 237 |
Receivables | 0 | 0 | 0 | 7 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 6 | 6 | 5 | 7 |
Total Current Assets | 168 | 186 | 207 | 231 | 244 |
Net Property & Equipment | 3 | 4 | 4 | 4 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 6 | 6 | 6 | 7 |
Total Assets | 180 | 199 | 221 | 249 | 263 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 8 | 3 | 2 |
Current Portion Long-Term Debt | 3 | 1 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 7 | 6 | 11 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 18 | 16 | 18 | 17 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 8 | 9 | 10 | 10 | 10 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 30 | 34 | 33 | 31 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 545 | 542 | 538 | 535 | 528 |
Retained Earnings | -394 | -372 | -351 | -319 | -295 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 151 | 169 | 188 | 216 | 232 |
Total Liabilities & Shareholder's Equity | 180 | 199 | 221 | 249 | 263 |
Total Common Equity | 151 | 169 | 188 | 216 | 232 |
Shares Outstanding | 72.80 | 72.80 | 72.60 | 72.60 | 72.40 |
Book Value Per Share | 2.07 | 2.32 | 2.58 | 2.98 | 3.21 |